Arvinas Earnings Call: High Science, Tight Cash

Arvinas Holding Company ((ARVN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Arvinas Holding’s latest earnings call blended optimism over rapid scientific progress with clear financial strain. Management showcased multiple advancing clinical programs and strong preclinical data, while also acknowledging a steep drop in cash and quarterly revenue. The tone balanced confidence in 2026 catalysts with concern over funding needs and competitive pressures.

Pipeline Expansion Drives Clinical Momentum

Arvinas now has four clinical-stage programs—ARV-102, ARV-806, ARV-393 and ARV-027—with multiple readouts slated for 2026. The company also initiated first-in-human dosing for ARV-027 and expects its HPK1 degrader ARV-6723 to enter the clinic later in 2026, underscoring an aggressive push to convert its discovery engine into clinical assets.

ARV-102 Shows Strong LRRK2 Biomarker Engagement

Lead neurology candidate ARV-102 delivered over 50% reduction in LRRK2 in cerebrospinal fluid of healthy volunteers and engaged downstream pathway biomarkers GPNMB and CD68. Phase 1 patient data will be presented orally at the AD/PD meeting, and a Phase 1b study in PSP is planned for the first half of 2026 with a possible registrational trial late 2026 pending regulators.

KRAS G12D Degrader ARV-806 Moves Quickly

In oncology, enrollment for ARV-806 has progressed faster than expected, positioning Arvinas for first clinical data disclosures in 2026. Preclinical studies showed more than 25-fold greater potency versus current clinical KRAS G12D inhibitors and degradation of both active and inactive KRAS, a potential differentiator in a crowded KRAS field.

Early Signals and Combo Potential for ARV-393

ARV-393, a BCL6 degrader, is advancing through Phase 1 dose escalation with responses seen in both B- and T-cell lymphomas even at exposures below predicted efficacious levels. The candidate has shown robust BCL6 degradation and tolerability, while preclinical combination with glofitamab delivered 91% tumor growth inhibition versus 36% for glofitamab alone.

Immuno-Oncology and Pan-KRAS Programs Impress Preclinically

Beyond the clinic, ARV-6723, a HPK1 degrader, produced strong single-agent and combination activity in preclinical models, outperforming HPK1 inhibitors and anti–PD-1 in several settings. Arvinas’ pan-KRAS degrader program showed selective KRAS degradation over HRAS and NRAS, activity across multiple mutants and amplified KRAS, with comparative inhibitor data planned for an upcoming scientific meeting.

Cost Cuts Drive Leaner Operating Model

The company highlighted sizable cost reductions as it recalibrates spending to match its tightened balance sheet. Q4 general and administrative expense fell to $23.0 million from $34.1 million year over year, while Q4 R&D dropped to $61.1 million from $83.3 million, and full-year G&A and R&D declined 42% and 18% respectively, reflecting deliberate expense discipline.

Runway Guidance Holds Despite Pressure

Despite the financial reset, management reiterated its guidance that existing cash can fund operations into 2028. This runway is intended to carry Arvinas through multiple Phase 1 and early Phase 2 data readouts and allow it to advance priority programs without immediate dependence on dilutive financing, assuming careful cost control and potential partnering.

Cash Balance Plunge Raises Financing Questions

The most striking financial metric was the collapse in cash, cash equivalents and marketable securities to just over $85 million at year-end 2025 from just over $1.0 billion a year earlier. The roughly 91% decline heightens sensitivity to upcoming milestones, potential partnership inflows and any future capital raises, making execution on both science and deals critical.

Q4 Revenue Hit by Licensing Decline

Quarterly revenue fell sharply to $9.5 million in Q4 2025 from $59.2 million in the prior-year quarter, an almost 84% decline tied largely to a $40.3 million drop in Novartis license revenue. Full-year revenue held roughly flat at $262.6 million versus $263.4 million, suggesting the Q4 impact reflects timing and structure of collaboration economics rather than core operational collapse.

Share Buybacks End as Liquidity Tightens

Arvinas completed a substantial share repurchase program before suspending further buybacks to conserve cash. The board-authorized plan resulted in about 10 million shares repurchased at an average price of $9.09 for a total of roughly $91.9 million, but the program’s halt underscores a shift from capital return to strict balance sheet preservation.

Competitive and Safety Risks Remain Material

Management acknowledged that several programs, especially KRAS G12D and pan-KRAS, face intense competition from drugs already in the clinic. To win share, assets like ARV-806 must demonstrate clearly superior response rates versus roughly 35% benchmarks, while LRRK2-targeting ARV-102 requires careful lung safety monitoring and longer-term data to validate its risk-benefit profile.

Reliance on Partnerships and Vepdegestrant Milestones

The company’s outlook is tightly linked to external partners and milestone streams, highlighted by the regulatory filing for vepdegestrant. Arvinas is working to secure an appropriate commercialization partner around the time of the upcoming regulatory decision, and the terms and timing of that arrangement could materially influence future revenue and strategic flexibility.

Guidance: 2026 Framed as Catalyst Year

Looking ahead, Arvinas framed 2026 as a pivotal catalyst year, with Phase 1 data expected from ARV-102, ARV-806 and ARV-393, plus ARV-027 dosing underway and ARV-6723 entering first-in-human studies later in the year. Management reiterated its cash runway into 2028, backed by lower non-GAAP quarterly expenses, while signaling that scientific milestones and partnering outcomes will be key to sustaining momentum.

Arvinas’ earnings call painted a picture of a biotech pushing a rich pipeline forward with compelling early data, even as its cash balance and revenue line come under strain. For investors, the story now hinges on whether upcoming 2026 readouts and partnership decisions can validate the science, differentiate assets in crowded markets and support the company’s ambitious runway guidance.